Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | GNAS complex locus | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | GTP-binding protein alpha subunit gna | GNAS complex locus | 394 aa | 450 aa | 28.7 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0075 | 0.5112 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.005 | 0.2008 | 0.2008 |
Plasmodium vivax | unspecified product | 0.0058 | 0.3048 | 0.2757 |
Brugia malayi | cathepsin L-like cysteine proteinase, identical | 0.0037 | 0.0402 | 0.0402 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0055 | 0.2649 | 0.2649 |
Brugia malayi | cathepsin L-like precursor | 0.0076 | 0.526 | 0.526 |
Brugia malayi | Cathepsin L-like cysteine proteinase | 0.0076 | 0.526 | 0.526 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.005 | 0.2008 | 0.2008 |
Loa Loa (eye worm) | hypothetical protein | 0.0037 | 0.0402 | 0.0402 |
Trypanosoma cruzi | cysteine peptidase, clan CA, family C1, cathepsin L-like, putative | 0.0076 | 0.526 | 0.5061 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2649 | 0.2649 |
Brugia malayi | Papain family cysteine protease containing protein | 0.0058 | 0.3048 | 0.3048 |
Mycobacterium ulcerans | hypothetical protein | 0.0075 | 0.5112 | 0.5 |
Schistosoma mansoni | cathepsin F (C01 family) | 0.0076 | 0.526 | 0.526 |
Echinococcus multilocularis | cathepsin L | 0.0058 | 0.3048 | 0.0543 |
Echinococcus granulosus | cathepsin L | 0.0058 | 0.3048 | 0.0543 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0055 | 0.2649 | 0.2649 |
Brugia malayi | cathepsin F-like cysteine proteinase | 0.0037 | 0.0402 | 0.0402 |
Schistosoma mansoni | SmCL2-like peptidase (C01 family) | 0.0058 | 0.3048 | 0.3048 |
Brugia malayi | Cathepsin L-like precursor | 0.0037 | 0.0402 | 0.0402 |
Schistosoma mansoni | hypothetical protein | 0.0075 | 0.5112 | 0.5112 |
Echinococcus granulosus | cathepsin l1 | 0.0076 | 0.526 | 0.3552 |
Loa Loa (eye worm) | hypothetical protein | 0.0076 | 0.526 | 0.526 |
Mycobacterium tuberculosis | Conserved protein | 0.0075 | 0.5112 | 0.5 |
Mycobacterium tuberculosis | Long conserved protein | 0.0075 | 0.5112 | 0.5 |
Schistosoma mansoni | SmCL2-like peptidase (C01 family) | 0.0058 | 0.3048 | 0.3048 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2649 | 0.2649 |
Entamoeba histolytica | cysteine proteinase, putative | 0.0076 | 0.526 | 0.3182 |
Trypanosoma cruzi | cysteine peptidase (N-terminal), putative | 0.0058 | 0.3048 | 0.2757 |
Plasmodium vivax | vivapain-3 | 0.0058 | 0.3048 | 0.2757 |
Giardia lamblia | Hypothetical protein | 0.0075 | 0.5112 | 0.5 |
Echinococcus granulosus | cathepsin L cysteine protease | 0.0058 | 0.3048 | 0.0543 |
Mycobacterium tuberculosis | Hypothetical protein | 0.0075 | 0.5112 | 0.5 |
Mycobacterium leprae | Conserved hypothetical protein | 0.0075 | 0.5112 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0075 | 0.5112 | 0.5 |
Schistosoma mansoni | cathepsin s | 0.0037 | 0.0402 | 0.0402 |
Loa Loa (eye worm) | hypothetical protein | 0.005 | 0.2008 | 0.2008 |
Mycobacterium leprae | Conserved hypothetical protein | 0.0075 | 0.5112 | 0.5 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin L-like cysteine peptidase | 0.0076 | 0.526 | 0.3182 |
Trypanosoma cruzi | cysteine peptidase, putative | 0.0058 | 0.3048 | 0.2757 |
Brugia malayi | Thioredoxin family protein | 0.0075 | 0.5112 | 0.5112 |
Trichomonas vaginalis | Clan CA, family C1, cathepsin L-like cysteine peptidase | 0.0076 | 0.526 | 0.3182 |
Mycobacterium ulcerans | putative transglutaminase-like protein | 0.0075 | 0.5112 | 0.5 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.005 | 0.2008 | 0.2008 |
Trichomonas vaginalis | peptide N-glycanase, putative | 0.0075 | 0.5112 | 0.2969 |
Echinococcus multilocularis | Transglutaminase | 0.0075 | 0.5112 | 0.335 |
Brugia malayi | Cathepsin L-like precursor | 0.0076 | 0.526 | 0.526 |
Trypanosoma cruzi | cysteine proteinase, putative | 0.0058 | 0.3048 | 0.2757 |
Loa Loa (eye worm) | papain family cysteine protease containing protein | 0.0037 | 0.0402 | 0.0402 |
Loa Loa (eye worm) | hypothetical protein | 0.0037 | 0.0402 | 0.0402 |
Mycobacterium ulcerans | hypothetical protein | 0.0075 | 0.5112 | 0.5 |
Brugia malayi | Cathepsin L-like precursor | 0.0076 | 0.526 | 0.526 |
Loa Loa (eye worm) | hypothetical protein | 0.0037 | 0.0402 | 0.0402 |
Brugia malayi | Papain family cysteine protease containing protein | 0.0058 | 0.3048 | 0.3048 |
Onchocerca volvulus | 0.0076 | 0.526 | 0.0303 | |
Loa Loa (eye worm) | hypothetical protein | 0.0076 | 0.526 | 0.526 |
Mycobacterium ulcerans | transglutaminase family protein | 0.0075 | 0.5112 | 0.5 |
Trypanosoma cruzi | cysteine proteinase, putative | 0.0058 | 0.3048 | 0.2757 |
Trypanosoma cruzi | cysteine protease, putative | 0.0058 | 0.3048 | 0.2757 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0055 | 0.2649 | 0.2649 |
Schistosoma mansoni | SmCL2-like peptidase (C01 family) | 0.0058 | 0.3048 | 0.3048 |
Plasmodium vivax | vivapain-1 | 0.0058 | 0.3048 | 0.2757 |
Giardia lamblia | Transglutaminase/protease, putative | 0.0075 | 0.5112 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0076 | 0.526 | 0.526 |
Echinococcus granulosus | cysteine protease | 0.0058 | 0.3048 | 0.0543 |
Echinococcus granulosus | Transglutaminase | 0.0075 | 0.5112 | 0.335 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 6.3096 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (binding) | = 50.1187 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488813] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Eta. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588636] | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.